Ito A, Kawata K, Mitsuda T, Ichikawa S, Kawasaki K, Sudo T, Ikedo M, Yamaguchi H; International Conference on AIDS.
Int Conf AIDS. 1996 Jul 7-12; 11: 94 (abstract no. Mo.B.1229).
Yokohama City Univ. Hospital Clinical Laboratory, Yokohama, Japan. Fax: 81-45-787-2915.
Objective: To compare the isolated positive rate of Candida species in 31 HIV/AIDS patients with that in 64 healthy individuals and evaluate antifungal activities of various antifungal agents against isolated Candida species from oral cavities. Methods: Clinical isolates were collected repeatedly by swabbing oral cavities and cultured in CT medium and Candida GS medium at 35 degrees C for 48 to 72 hours. The antifungal sensitivities were measured by microdilution method. Results: Among 31 HIV/AIDS patients, Candida species were isolated in 21 cases (67.7%) at least once and 155 (32.9%) out of 471 samples were positive. Candida species were isolated in 8 cases (12.5%) of healthy group. Itraconazole showed the lowest IC80 Valus, then miconazole, fluconazole, flucytosine, and amphotericin B. None of the isolates showed resistance or low sensitivity, compared with the standard strains (ATCC90028, ATCC90029). Conclusion: Although, no azole resistant strains of Candida albicans were isolated in this study, we should take into consideration of the possibility of resistant strain appearance, especially fluconazole resistant ones. For oral/esophageal candidiasis in AIDS patients, we should keep in mind that the resistant strain would appear when recurrent episodes of Candida were found at repeated antifungal treatments.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Amphotericin B
- Antifungal Agents
- Candida
- Candida albicans
- Candidiasis
- Fluconazole
- Flucytosine
- HIV Infections
- Humans
- Itraconazole
- Miconazole
- Mouth
Other ID:
UI: 102217192
From Meeting Abstracts